Minireview: Primary aldosteronism - Changing concepts in diagnosis and treatment

被引:254
作者
Young, WF
机构
[1] Mayo Clin & Mayo Fdn, Mayo Med Sch, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Endocrinol Metab Nutr & Internal Med, Rochester, MN 55905 USA
关键词
PLASMA-RENIN-ACTIVITY; PLASMINOGEN-ACTIVATOR INHIBITOR-1; PRIMARY HYPERALDOSTERONISM; HYPERTENSIVE PATIENTS; HIGH PREVALENCE; SECONDARY HYPERTENSION; SCREENING-TEST; COMPUTED-TOMOGRAPHY; ANGIOTENSIN SYSTEM; ENDOTHELIAL-CELLS;
D O I
10.1210/en.2003-0279
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary aldosteronism affects 5-13% of patients with hypertension. Patients with hypertension and hypokalemia and most patients with treatment-resistant hypertension should undergo screening for primary aldosteronism with a plasma aldosterone concentration to plasma renin activity ratio. A high plasma aldosterone concentration to plasma renin activity ratio is a positive screening test result, a finding that warrants confirmatory testing. For those patients that want to pursue a surgical cure, the accurate distinction between the subtypes (unilateral vs. bilateral adrenal disease) of primary aldosteronism is a critical step. The subtype evaluation may require one or more tests, the first of which is imaging the adrenal glands with computed tomography, followed by selective use of adrenal venous sampling. Because of the deleterious cardiovascular effects of aldosterone, normalization of circulating aldosterone or aldosterone receptor blockade should be part of the management plan for all patients with primary aldosteronism. Unilateral laparoscopic adrenalectomy is an excellent treatment option for patients with unilateral aldosterone-producing adenoma. Bilateral idiopathic hyperaldosteronism should be treated medically. In addition, aldosterone-producing adenoma patients may be treated medically if the medical treatment includes mineralocorticoid receptor blockade.
引用
收藏
页码:2208 / 2213
页数:6
相关论文
共 81 条
[1]   Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients [J].
Abdelhamid, S ;
MullerLobeck, H ;
Pahl, S ;
Remberger, K ;
Bonhof, JA ;
Walb, D ;
Rockel, A .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (11) :1190-1195
[2]   MYOCARDIAL SCINTIGRAPHIC CHARACTERISTICS IN PATIENTS WITH PRIMARY ALDOSTERONISM [J].
ABE, M ;
HAMADA, M ;
MATSUOKA, H ;
SHIGEMATSU, Y ;
SUMIMOTO, T ;
HIWADA, K .
HYPERTENSION, 1994, 23 (01) :I164-I167
[3]   ASSOCIATION OF THE RENIN SODIUM PROFILE WITH THE RISK OF MYOCARDIAL-INFARCTION IN PATIENTS WITH HYPERTENSION [J].
ALDERMAN, MH ;
MADHAVAN, S ;
OOI, WL ;
COHEN, H ;
SEALEY, JE ;
LARAGH, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (16) :1098-1104
[4]  
ANDERSEN GS, 1988, J HUM HYPERTENS, V2, P187
[5]   THE EFFECT OF AGE ON PREVALENCE OF SECONDARY FORMS OF HYPERTENSION IN 4429 CONSECUTIVELY REFERRED PATIENTS [J].
ANDERSON, GH ;
BLAKEMAN, N ;
STREETEN, DHP .
JOURNAL OF HYPERTENSION, 1994, 12 (05) :609-615
[6]   DIAGNOSIS AND TREATMENT OF PRIMARY HYPERALDOSTERONISM [J].
BLUMENFELD, JD ;
SEALEY, JE ;
SCHLUSSEL, Y ;
VAUGHAN, ED ;
SOS, TA ;
ATLAS, SA ;
MULLER, FB ;
ACEVEDO, R ;
ULICK, S ;
LARAGH, JH .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (11) :877-885
[7]  
BRAVO EL, 1988, HYPERTENSION, V11, P207
[8]   REMODELING OF THE RAT RIGHT-AND-LEFT-VENTRICLES IN EXPERIMENTAL-HYPERTENSION [J].
BRILLA, CG ;
PICK, R ;
TAN, LB ;
JANICKI, JS ;
WEBER, KT .
CIRCULATION RESEARCH, 1990, 67 (06) :1355-1364
[9]   Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 [J].
Brown, NJ ;
Agirbasli, MA ;
Williams, GH ;
Litchfield, WR ;
Vaughan, DE .
HYPERTENSION, 1998, 32 (06) :965-971
[10]   Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production [J].
Brown, NJ ;
Kim, KS ;
Chen, YQ ;
Blevins, LS ;
Nadeau, JH ;
Meranze, SG ;
Vaughan, DE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (01) :336-344